Vitalina Bodenko - Search Results

Year	Number of Results
2022	5
2023	5
2024	1

1

Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.

Yin W, Xu T, Ding H, Zhang J, Bodenko V, Tretyakova MS, Belousov MV, Liu Y, Oroujeni M, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A. Yin W, et al. Among authors: bodenko v. J Control Release. 2023 Mar;355:515-527. doi: 10.1016/j.jconrel.2023.02.005. Epub 2023 Feb 14. J Control Release. 2023. PMID: 36773960 Free article.

2

Radionuclide Therapy of HER2-Expressing Xenografts Using [¹⁷⁷Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab.

Liu Y, Xu T, Vorobyeva A, Loftenius A, Bodenko V, Orlova A, Frejd FY, Tolmachev V. Liu Y, et al. Among authors: bodenko v. Cancers (Basel). 2023 Apr 22;15(9):2409. doi: 10.3390/cancers15092409. Cancers (Basel). 2023. PMID: 37173878 Free PMC article.

3

¹⁷⁷Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry.

Abouzayed A, Seitova K, Lundmark F, Bodenko V, Oroujeni M, Tolmachev V, Rosenström U, Orlova A. Abouzayed A, et al. Among authors: bodenko v. Front Oncol. 2023 Sep 27;13:1221103. doi: 10.3389/fonc.2023.1221103. eCollection 2023. Front Oncol. 2023. PMID: 37829345 Free PMC article.

4

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2.

Xu T, Zhang J, Oroujeni M, Tretyakova MS, Bodenko V, Belousov MV, Orlova A, Tolmachev V, Vorobyeva A, Gräslund T. Xu T, et al. Among authors: bodenko v. Pharmaceutics. 2022 Feb 26;14(3):522. doi: 10.3390/pharmaceutics14030522. Pharmaceutics. 2022. PMID: 35335898 Free PMC article.

5

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis.

Liu Y, Güler R, Liao Y, Vorobyeva A, Widmark O, Meuleman TJ, Koijen A, van den Bos LJ, Naasz R, Bodenko V, Orlova A, Ekblad C, Tolmachev V, Frejd FY. Liu Y, et al. Among authors: bodenko v. Pharmaceutics. 2022 Nov 19;14(11):2519. doi: 10.3390/pharmaceutics14112519. Pharmaceutics. 2022. PMID: 36432709 Free PMC article.

6

Preclinical Evaluation of a New Format of ⁶⁸Ga- and ¹¹¹In-Labeled Affibody Molecule Z_IGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT.

Liu Y, Yu S, Xu T, Bodenko V, Orlova A, Oroujeni M, Rinne SS, Tolmachev V, Vorobyeva A, Gräslund T. Liu Y, et al. Among authors: bodenko v. Pharmaceutics. 2022 Jul 15;14(7):1475. doi: 10.3390/pharmaceutics14071475. Pharmaceutics. 2022. PMID: 35890370 Free PMC article.

7

Direct In Vivo Comparison of ^99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy.

Tolmachev V, Bodenko V, Oroujeni M, Deyev S, Konovalova E, Schulga A, Lindbo S, Hober S, Bragina O, Orlova A, Vorobyeva A. Tolmachev V, et al. Among authors: bodenko v. Int J Mol Sci. 2022 Dec 2;23(23):15181. doi: 10.3390/ijms232315181. Int J Mol Sci. 2022. PMID: 36499504 Free PMC article.

8

Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with ^99mTc and ¹²⁵I.

Tolmachev V, Bodenko V, Orlova A, Schulga A, Deyev SM, Vorobyeva A. Tolmachev V, et al. Among authors: bodenko v. Oncol Lett. 2022 Nov 17;25(1):12. doi: 10.3892/ol.2022.13598. eCollection 2023 Jan. Oncol Lett. 2022. PMID: 36478911 Free PMC article.

9

Synthesis, ¹²³I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures.

Hasnowo LA, Larkina MS, Plotnikov E, Bodenko V, Yuldasheva F, Stasyuk E, Petrov SA, Zyk NY, Machulkin AE, Vorozhtsov NI, Beloglazkina EK, Nenajdenko VG, Tolmachev V, Orlova A, Majouga AG, Yusubov MS. Hasnowo LA, et al. Among authors: bodenko v. Int J Mol Sci. 2023 Jul 30;24(15):12206. doi: 10.3390/ijms241512206. Int J Mol Sci. 2023. PMID: 37569582 Free PMC article.

10

Half-life extension via ADB-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

Zhang J, Bodenko V, Larkina M, Bezverkhniaia E, Xu T, Liao Y, Abouzayed A, Plotnikov E, Tretyakova M, Yuldasheva F, Belousov MV, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A. Zhang J, et al. Among authors: bodenko v. J Control Release. 2024 Apr 30:S0168-3659(24)00280-3. doi: 10.1016/j.jconrel.2024.04.051. Online ahead of print. J Control Release. 2024. PMID: 38697314

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

10 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year